8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Feb 25, 2026·SEC
Sarepta Therapeutics, Inc.(SRPT)Earnings, Financials & Key Ratios
SRPT•NASDAQ
Price updated Jun 19, 2026
AboutSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$2.2B+15.6%
- EBITDA-$613M-339.7%
- Net Income-$713M-403.3%
- EPS (Diluted)-7.13-404.7%
- Gross Margin59.9%-28.0%
- EBITDA Margin-27.9%-307.4%
- Operating Margin-29.92%-361.0%
- Net Margin-32.45%-362.4%
- ROE-53.47%-371.3%
SRPT Key Insights
Sarepta Therapeutics, Inc. (SRPT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 32.4%
- ✓Share count reduced 2.9% through buybacks
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SRPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SRPT Price & Volume
Sarepta Therapeutics, Inc. (SRPT) stock price & volume — 10-year historical chart
Loading chart...
SRPT Growth Metrics
Sarepta Therapeutics, Inc. (SRPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years111.06%
5 Years32.41%
3 Years33.06%
TTM-2.2%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM126.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM64.44%
Return on Capital
10 Years-28.17%
5 Years-13.01%
3 Years-8.99%
Last Year-23.98%
SRPT Recent Earnings
Sarepta Therapeutics, Inc. (SRPT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$3.16+223.8%
$0.98
Rev
$731M+54.1%
$474M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$3.58-247.6%
$1.03
Rev
$443M+19.8%
$370M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.13-1400.0%
$0.01
Rev
$399M+2.0%
$391M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$2.02+142.8%
$0.83
Rev
$611M+15.2%
$531M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $3.16vs $0.98+223.8% | $731Mvs $474M+54.1% |
| Q1 2026 | Feb 25, 2026 | $3.58vs $1.03-247.6% | $443Mvs $370M+19.8% |
| Q4 2025 | Nov 3, 2025 | $0.13vs $0.01-1400.0% | $399Mvs $391M+2.0% |
| Q3 2025 | Aug 6, 2025 | $2.02vs $0.83+142.8% | $611Mvs $531M+15.2% |
Based on last 12 quarters of dataView full earnings history →
SRPT Peer Comparison
Sarepta Therapeutics, Inc. (SRPT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare SRPT vs Peers
Sarepta Therapeutics, Inc. (SRPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRPT Income Statement
Sarepta Therapeutics, Inc. (SRPT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 154.58M | 301.03M | 380.83M | 540.1M | 701.89M | 933.01M | 1.24B | 1.9B | 2.2B | 2.18B |
Revenue Growth % | 2751.58% | 94.74% | 26.51% | 41.82% | 29.96% | 32.93% | 33.26% | 52.97% | 15.58% | -2.2% |
Cost of Goods Sold | 7.35M | 34.19M | 56.59M | 63.38M | 97.05M | 139.99M | 150.34M | 319.1M | 881.5M | 702.04M |
COGS % of Revenue | 4.76% | 11.36% | 14.86% | 11.74% | 13.83% | 15% | 12.09% | 16.78% | 40.1% | - |
Gross Profit | 147.23M▲ 0% | 266.84M▲ 81.2% | 324.25M▲ 21.5% | 476.72M▲ 47.0% | 604.84M▲ 26.9% | 793.02M▲ 31.1% | 1.09B▲ 37.8% | 1.58B▲ 44.8% | 1.32B▼ 16.8% | 751.34M▲ 0% |
Gross Margin % | 95.24% | 88.64% | 85.14% | 88.26% | 86.17% | 85% | 87.91% | 83.22% | 59.9% | 34.4% |
Gross Profit Growth % | 2682.67% | 81.24% | 21.51% | 47.02% | 26.88% | 31.11% | 37.83% | 44.82% | -16.81% | - |
Operating Expenses | 290.44M | 610.47M | 1.03B | 1.04B | 1.06B | 1.33B | 1.36B | 1.36B | 1.97B | 1.41B |
OpEx % of Revenue | 187.89% | 202.79% | 270.41% | 192.72% | 151.67% | 142.47% | 109.45% | 71.76% | 89.82% | - |
Selling, General & Admin | 122.68M | 207.76M | 284.81M | 317.88M | 282.66M | 451.42M | 481.87M | 557.87M | 478.94M | 467.04M |
SG&A % of Revenue | 79.36% | 69.02% | 74.79% | 58.86% | 40.27% | 48.38% | 38.76% | 29.33% | 21.79% | - |
Research & Development | 166.71M | 401.84M | 560.91M | 722.34M | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B | 902.58M |
R&D % of Revenue | 107.84% | 133.49% | 147.28% | 133.74% | 109.87% | 94.01% | 70.57% | 42.3% | 69.24% | - |
Other Operating Expenses | 1.98M | -656K | 184.09M | 662K | 10.71M | 714K | 1.56M | 2.4M | -26.5M | 2.67M |
Operating Income | -171.64M▲ 0% | -343.63M▼ 100.2% | -705.56M▼ 105.3% | -564.16M▲ 20.0% | -459.71M▲ 18.5% | -536.2M▼ 16.6% | -267.82M▲ 50.1% | 218.08M▲ 181.4% | -657.77M▼ 401.6% | -40.96M▲ 0% |
Operating Margin % | -111.03% | -114.15% | -185.27% | -104.46% | -65.5% | -57.47% | -21.54% | 11.47% | -29.92% | -1.88% |
Operating Income Growth % | 35.65% | -100.21% | -105.33% | 20.04% | 18.51% | -16.64% | 50.05% | 181.43% | -401.62% | - |
EBITDA | -163.55M | -331.38M | -681.06M | -524.42M | -421.69M | -494.34M | -223.43M | 255.81M | -613.25M | -6.42M |
EBITDA Margin % | -105.8% | -110.08% | -178.84% | -97.1% | -60.08% | -52.98% | -17.97% | 13.45% | -27.9% | -0.29% |
EBITDA Growth % | 37.37% | -102.62% | -105.52% | 23% | 19.59% | -17.23% | 54.8% | 214.49% | -339.73% | 91.8% |
D&A (Non-Cash Add-back) | 8.09M | 12.24M | 24.5M | 39.74M | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M | 34.54M |
EBIT | -42.83M | -328.9M | -683.21M | -493.12M | -355.42M | -636.72M | -498.09M | 279.17M | -692.49M | -285.07M |
Net Interest Income | -3.99M | -26.9M | -23.43M | -56.98M | -63.01M | -25.52M | 63.96M | 53.38M | 9.84M | 3.54M |
Interest Income | 1.81M | 6.81M | 7.24M | 2.97M | 511K | 27.72M | 85.97M | 71.77M | 19.57M | 23.9M |
Interest Expense | 5.78M | 33.71M | 30.67M | 59.95M | 63.52M | 53.25M | 22.01M | 18.39M | 9.73M | 20.36M |
Other Income/Expense | 123.01M | -18.98M | -8.32M | 11.1M | 40.76M | -153.76M | -252.27M | 42.69M | -44.45M | 65.43M |
Pretax Income | -48.63M▲ 0% | -362.61M▼ 645.7% | -713.88M▼ 96.9% | -553.07M▲ 22.5% | -418.95M▲ 24.2% | -689.96M▼ 64.7% | -520.1M▲ 24.6% | 260.77M▲ 150.1% | -702.23M▼ 369.3% | 24.47M▲ 0% |
Pretax Margin % | -31.46% | -120.45% | -187.45% | -102.4% | -59.69% | -73.95% | -41.83% | 13.71% | -31.94% | 1.12% |
Income Tax | 2.06M | -692K | 1.2M | 1.06M | -168K | 13.53M | 15.88M | 25.54M | 11.19M | -40.59M |
Effective Tax Rate % | -4.24% | 0.19% | -0.17% | -0.19% | 0.04% | -1.96% | -3.05% | 9.79% | -1.59% | -165.9% |
Net Income | -50.69M▲ 0% | -361.92M▼ 614.0% | -715.08M▼ 97.6% | -554.13M▲ 22.5% | -418.78M▲ 24.4% | -703.49M▼ 68.0% | -535.98M▲ 23.8% | 235.24M▲ 143.9% | -713.41M▼ 403.3% | 65.06M▲ 0% |
Net Margin % | -32.79% | -120.23% | -187.77% | -102.6% | -59.66% | -75.4% | -43.11% | 12.37% | -32.45% | 2.98% |
Net Income Growth % | 81.03% | -614.01% | -97.58% | 22.51% | 24.43% | -67.99% | 23.81% | 143.89% | -403.27% | 126.19% |
Net Income (Continuing) | -50.69M | -361.92M | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M | 235.24M | -713.41M | 65.06M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.86▲ 0% | -5.46▼ 534.9% | -9.71▼ 77.8% | -7.11▲ 26.8% | -5.15▲ 27.6% | -8.03▼ 55.9% | -5.80▲ 27.8% | 2.34▲ 140.3% | -7.13▼ 404.7% | 0.53▲ 0% |
EPS Growth % | 84.34% | -534.88% | -77.84% | 26.78% | 27.57% | -55.92% | 27.77% | 140.34% | -404.7% | 64.44% |
EPS (Basic) | -0.86 | -5.46 | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 2.47 | -7.13 | - |
Diluted Shares Outstanding | 58.82M | 66.25M | 73.61M | 77.96M | 81.26M | 87.56M | 92.4M | 107.88M | 104.79M | 121.92M |
Basic Shares Outstanding | 58.82M | 66.25M | 73.61M | 77.96M | 81.26M | 87.56M | 92.4M | 95.08M | 104.79M | 104.99M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SRPT Balance Sheet
Sarepta Therapeutics, Inc. (SRPT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.23B | 1.43B | 1.47B | 2.49B | 2.6B | 2.56B | 2.58B | 3.07B | 2.54B | 2.31B |
Cash & Short-Term Investments | 1.08B | 1.17B | 1.12B | 1.94B | 2.12B | 1.99B | 1.68B | 1.35B | 939.65M | 653.19M |
Cash Only | 599.69M | 370.83M | 835.08M | 1.5B | 2.12B | 966.78M | 428.43M | 1.1B | 801.28M | 464.45M |
Short-Term Investments | 479.37M | 803.08M | 289.67M | 435.92M | 0 | 1.02B | 1.25B | 251.78M | 138.37M | 188.74M |
Accounts Receivable | 29.47M | 49.04M | 93.94M | 138.58M | 172.75M | 261.6M | 436.98M | 649.73M | 398.23M | 394.82M |
Days Sales Outstanding | 69.58 | 59.47 | 90.03 | 93.65 | 89.83 | 102.34 | 128.28 | 124.69 | 66.12 | 81.23 |
Inventory | 83.61M | 125.44M | 171.38M | 231.96M | 186.21M | 203.97M | 322.86M | 749.96M | 914.74M | 1B |
Days Inventory Outstanding | 4.15K | 1.34K | 1.11K | 1.34K | 700.34 | 531.82 | 783.83 | 857.84 | 378.76 | 518.23 |
Other Current Assets | 22.41M | 62.14M | 59.52M | 138.5M | 5.3M | 6.82M | 12.48M | 9.21M | 285.31M | 260.76M |
Total Non-Current Assets | 79.32M | 215.89M | 353.91M | 499.52M | 543.88M | 570.5M | 685.25M | 889.71M | 811.76M | 869.06M |
Property, Plant & Equipment | 43.16M | 97.02M | 167.55M | 282.19M | 236.69M | 244.99M | 357.11M | 488.65M | 470.62M | 460.3M |
Fixed Asset Turnover | 3.58x | 3.10x | 2.27x | 1.91x | 2.97x | 3.81x | 3.48x | 3.89x | 4.67x | 4.49x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 14.36M | 11.57M | 12.5M | 13.63M | 14.24M | 7.58M | 29.62M | 26.89M | 28.95M | 0 |
Long-Term Investments | 9.98M | 107.29M | 41.5M | 48.11M | 34.89M | 31.32M | 6.53M | 136.87M | 1.05M | 126.79M |
Other Non-Current Assets | 21.81M | 107.29M | 132.36M | 155.59M | 258.06M | 286.62M | 291.99M | 237.3M | 311.15M | 326.82M |
Total Assets | 1.31B▲ 0% | 1.64B▲ 25.5% | 1.82B▲ 11.0% | 2.98B▲ 63.7% | 3.15B▲ 5.5% | 3.13B▼ 0.6% | 3.26B▲ 4.4% | 3.96B▲ 21.4% | 3.35B▼ 15.5% | 3.18B▲ 0% |
Asset Turnover | 0.12x | 0.18x | 0.21x | 0.18x | 0.22x | 0.30x | 0.38x | 0.48x | 0.66x | 0.64x |
Asset Growth % | 208.41% | 25.54% | 11.01% | 63.74% | 5.47% | -0.62% | 4.35% | 21.4% | -15.48% | -19.24% |
Total Current Liabilities | 88.33M | 173.69M | 264.77M | 416.03M | 452.73M | 619.6M | 653.66M | 731.68M | 1.1B | 499.16M |
Accounts Payable | 8.47M | 33.83M | 68.09M | 111.09M | 76.74M | 95.88M | 164.92M | 214.44M | 280.84M | 70.38M |
Days Payables Outstanding | 420.3 | 361.11 | 439.23 | 639.74 | 288.62 | 249.98 | 400.38 | 245.29 | 116.29 | 75.64 |
Short-Term Debt | 6.17M | 0 | 7.85M | 20.93M | 0 | 0 | 105.48M | 0 | 11.2M | 0 |
Deferred Revenue (Current) | 3.32M | 3.3M | 0 | 89.24M | 89.24M | 89.24M | 50.42M | 130.26M | 443.4M | 1.44B |
Other Current Liabilities | 55.03M | 111.56M | 145.59M | 143.96M | 110.44M | 134.73M | 178.81M | 200.28M | 359.86M | 312.75M |
Current Ratio | 13.91x | 8.21x | 5.55x | 5.97x | 5.75x | 4.13x | 3.95x | 4.20x | 2.32x | 4.63x |
Quick Ratio | 12.96x | 7.49x | 4.90x | 5.42x | 5.34x | 3.80x | 3.45x | 3.18x | 1.48x | 2.62x |
Cash Conversion Cycle | 3.8K | 1.04K | 756.26 | 789.72 | 501.55 | 384.18 | 511.73 | 737.24 | 328.6 | 523.82 |
Total Non-Current Liabilities | 430.42M | 436.11M | 739.87M | 1.81B | 1.77B | 2.12B | 1.75B | 1.7B | 1.11B | 1.17B |
Long-Term Debt | 424.88M | 420.55M | 681.9M | 992.49M | 1.1B | 1.54B | 1.13B | 1.14B | 828.97M | 1.04B |
Capital Lease Obligations | 0 | 0 | 47.72M | 80.37M | 41.51M | 57.58M | 140.97M | 192.47M | 199.38M | 628.84M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5.54M | 15.55M | 10.25M | 70.58M | 54.6M | 36.94M | 41.1M | 49.15M | 1.53M | 138M |
Total Liabilities | 518.75M | 609.8M | 1B | 2.22B | 2.22B | 2.74B | 2.41B | 2.44B | 2.21B | 1.67B |
Total Debt | 431.05M | 420.55M | 737.47M | 1.09B | 1.15B | 1.62B | 1.4B | 1.34B | 1.04B | 1.04B |
Net Debt | -168.64M | 49.73M | -97.61M | -408.86M | -962.43M | 650.58M | 968.38M | 240.06M | 238.27M | 572.22M |
Debt / Equity | 0.55x | 0.41x | 0.90x | 1.44x | 1.24x | 4.20x | 1.63x | 0.88x | 0.91x | 0.69x |
Debt / EBITDA | - | - | - | - | - | - | - | 5.25x | - | -161.50x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.94x | - | -89.14x |
Interest Coverage | -7.41x | -9.76x | -22.28x | -8.23x | -5.60x | -11.96x | -22.63x | 15.18x | -71.16x | -14.00x |
Total Equity | 789.22M▲ 0% | 1.03B▲ 30.8% | 818.19M▼ 20.7% | 761.76M▼ 6.9% | 928.01M▲ 21.8% | 384.95M▼ 58.5% | 859.34M▲ 123.2% | 1.53B▲ 77.8% | 1.14B▼ 25.3% | 1.51B▲ 0% |
Equity Growth % | 134.4% | 30.8% | -20.74% | -6.9% | 21.82% | -58.52% | 123.23% | 77.78% | -25.34% | 40.51% |
Book Value per Share | 13.42 | 15.58 | 11.11 | 9.77 | 11.42 | 4.40 | 9.30 | 14.16 | 10.88 | 12.35 |
Total Shareholders' Equity | 789.22M | 1.03B | 818.19M | 761.76M | 928.01M | 384.95M | 859.34M | 1.53B | 1.14B | 1.51B |
Common Stock | 6K | 7K | 8K | 8K | 9K | 9K | 9K | 10K | 11K | 11K |
Retained Earnings | -1.22B | -1.58B | -2.29B | -2.85B | -3.21B | -3.91B | -4.45B | -4.21B | -4.88B | -4.55B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25.26M | 0 |
Accumulated OCI | -379K | -99K | 50K | 3K | -20K | -1.66M | 918K | -218K | 272K | -121K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SRPT Cash Flow Statement
Sarepta Therapeutics, Inc. (SRPT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -232M | -388.66M | -456.46M | 107.47M | -443.17M | -325.35M | -500.99M | -205.79M | -205.48M | 175.28M |
Operating CF Margin % | -150.08% | -129.11% | -119.86% | 19.9% | -63.14% | -34.87% | -40.29% | -10.82% | -9.35% | - |
Operating CF Growth % | 5.62% | -67.53% | -17.45% | 123.54% | -512.38% | 26.59% | -53.99% | 58.92% | 0.15% | 1836.18% |
Net Income | -50.69M | -361.92M | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M | 235.24M | -713.41M | 65.06M |
Depreciation & Amortization | 8.09M | 12.24M | 24.5M | 26.91M | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M | 48.25M |
Stock-Based Compensation | 30.46M | 50.13M | 78.6M | 108.07M | 113.94M | 233.02M | 182.51M | 184.3M | 123.4M | 81.97M |
Deferred Taxes | -83K | -1.41M | 0 | 10.64M | 15.81M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -122.32M | 20.19M | 222.39M | -38.09M | -94M | 142.73M | 289.16M | 53.56M | 261.98M | 206.44M |
Working Capital Changes | -97.46M | -107.89M | -66.88M | 554.06M | -98.17M | -39.47M | -481.09M | -716.61M | 78.04M | -226.44M |
Change in Receivables | -24.24M | -19.58M | -41.84M | -10.46M | -51.65M | -61.64M | -185.7M | -201.66M | 203.75M | 264.55M |
Change in Inventory | -70.79M | -41.84M | -45.93M | -60.58M | -83.77M | -50.78M | -147.71M | -395.17M | -301.09M | -193.49M |
Change in Payables | 12.93M | 90.16M | 122.98M | 42M | 23.3M | 147.57M | -50.13M | 110.65M | 104.27M | 39.15M |
Cash from Investing | -178.81M | -370.49M | 286.73M | -121.72M | 495.41M | -1.05B | -165.8M | 755.56M | 69.64M | 226.43M |
Capital Expenditures | -21.21M | -64.34M | -59.63M | -82.2M | -38.49M | -30.82M | -76.11M | -136.96M | -101.97M | -61.4M |
CapEx % of Revenue | 13.72% | 21.37% | 15.66% | 15.22% | 5.48% | 3.3% | 6.12% | 7.2% | 4.64% | 2.81% |
Acquisitions | -9.21M | 3.19M | -172.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 134.22M | -3.19M | -3.08M | 104.57M | 97.89M | -1.43M | 90.76M | -10M | -253.69M | 164.03M |
Cash from Financing | 888.08M | 530.15M | 642.55M | 682.32M | 561.57M | 232.51M | 125M | 124.81M | -168.34M | -180.57M |
Debt Issued (Net) | 584.95M | -33.48M | 245.63M | 291.15M | 0 | 304.17M | 0 | -68K | -162.59M | -159.07M |
Equity Issued (Net) | 353.96M | 0 | 365.35M | 312.05M | 548.53M | 0 | 0 | 0 | 11.3M | 20.44M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25.01M | 0 |
Other Financing | -50.83M | 563.63M | 31.57M | 79.12M | 13.04M | -71.66M | 125M | 124.87M | -17.06M | -41.94M |
Net Change in Cash | 477.27M▲ 0% | -229M▼ 148.0% | 472.82M▲ 306.5% | 668.07M▲ 41.3% | 613.81M▼ 8.1% | -1.14B▼ 285.7% | -541.79M▲ 52.5% | 674.58M▲ 224.5% | -304.18M▼ 145.1% | 221.13M▲ 0% |
Free Cash Flow | -253.21M▲ 0% | -453M▼ 78.9% | -516.09M▼ 13.9% | 25.26M▲ 104.9% | -481.66M▼ 2006.5% | -357.6M▲ 25.8% | -588.34M▼ 64.5% | -352.74M▲ 40.0% | -307.45M▲ 12.8% | 107.14M▲ 0% |
FCF Margin % | -163.8% | -150.48% | -135.52% | 4.68% | -68.62% | -38.33% | -47.32% | -18.55% | -13.99% | 4.91% |
FCF Growth % | -0.21% | -78.9% | -13.93% | 104.9% | -2006.52% | 25.76% | -64.53% | 40.04% | 12.84% | 115.36% |
FCF per Share | -4.30 | -6.84 | -7.01 | 0.32 | -5.93 | -4.08 | -6.37 | -3.27 | -2.93 | 0.88 |
FCF Conversion (FCF/Net Income) | 4.58x | 1.07x | 0.64x | -0.19x | 1.06x | 0.46x | 0.93x | -0.87x | 0.29x | 1.65x |
Interest Paid | 1.91M | 11.31M | 8.55M | 34.42M | 55.95M | 44.42M | 15.92M | 15.86M | 0 | 6.77M |
Taxes Paid | 5.34M | 1.55M | 933K | 2.51M | 583K | 1.7M | 15.08M | 22.59M | 0 | 20.41M |
SRPT Key Ratios
Sarepta Therapeutics, Inc. (SRPT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -9% | -39.74% | -77.29% | -70.15% | -49.57% | -107.16% | -86.15% | 19.71% | -53.47% | 4.89% |
Return on Invested Capital (ROIC) | -30.25% | -30.27% | -58.71% | -78.83% | -216.52% | -80.34% | -14.03% | 9.1% | -31.36% | -1.61% |
Gross Margin | 95.24% | 88.64% | 85.14% | 88.26% | 86.17% | 85% | 87.91% | 83.22% | 59.9% | 34.4% |
Net Margin | -32.79% | -120.23% | -187.77% | -102.6% | -59.66% | -75.4% | -43.11% | 12.37% | -32.45% | 2.98% |
Debt / Equity | 0.55x | 0.41x | 0.90x | 1.44x | 1.24x | 4.20x | 1.63x | 0.88x | 0.91x | 0.69x |
Interest Coverage | -7.41x | -9.76x | -22.28x | -8.23x | -5.60x | -11.96x | -22.63x | 15.18x | -71.16x | -14.00x |
FCF Conversion | 4.58x | 1.07x | 0.64x | -0.19x | 1.06x | 0.46x | 0.93x | -0.87x | 0.29x | 1.65x |
Revenue Growth | 2751.58% | 94.74% | 26.51% | 41.82% | 29.96% | 32.93% | 33.26% | 52.97% | 15.58% | -2.2% |
Related:SRPT Dividend History·SRPT Revenue History·SRPT Price History·SRPT P/E History·SRPT Financial Ratios·SRPT Institutional Holders
SRPT SEC Filings & Documents
Sarepta Therapeutics, Inc. (SRPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
SRPT Frequently Asked Questions
Sarepta Therapeutics, Inc. (SRPT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sarepta Therapeutics, Inc. (SRPT) reported $2.18B in revenue for fiscal year 2025. This represents a 2184084% increase from $0.1M in 1996.
Sarepta Therapeutics, Inc. (SRPT) grew revenue by 15.6% over the past year. This is strong growth.
Yes, Sarepta Therapeutics, Inc. (SRPT) is profitable, generating $65.1M in net income for fiscal year 2025 (-32.5% net margin).
Dividend & Returns
Sarepta Therapeutics, Inc. (SRPT) has a return on equity (ROE) of -53.5%. Negative ROE indicates the company is unprofitable.
Sarepta Therapeutics, Inc. (SRPT) generated $107.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.